You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恩華藥業(002262.SZ)漲停創逾2年新高 引進的急性鎮痛類創新藥Olinvyk獲FDA批准上市
格隆匯 08-10 11:05
格隆匯8月10日丨恩華藥業(002262.SZ)漲停,報20.02元,創2018年7月以來新高,暫成交8.4億元,最新總市值204億元。該股年內累漲73%。美國食品藥品監督管理局(FDA)近日批准了阿片類藥物Olinvyk,用於治療成人中度至重度急性疼痛。Olinvyk是Trevena公司開發的一款急性疼痛治療藥物,該藥適用於醫院或其他受控臨牀環境(例如住院和門診手術期間)的短期靜脈內使用。恩華藥業2018年已獲Trevena授權,獨家許可恩華藥業在中國開展該產品授權適應證的開發及銷售。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account